Breadcrumb

[A18-66] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-10-01 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of dossier assessment  [PDF, 83 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G16-02] Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed

[A19-16] Daratumumab (multiple myeloma) - Addendum to Commission A18-66
Status: Commission completed

[A17-40] Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-01-02 Executive summary of dossier assessment (German version) 83 kBPDFdownload file
2019-01-02 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2019-03-22 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close